Bio.services has established a manufacturability assessment platform for a full cascade of therapeutic antibody drug discovery and development, ranging from a series of approaches starting with a screening assay to developability assessment and optimization, covering humanization/deimmunization, immunogenicity assessment, epitope predicting and mapping, reengineering and manufacturability assessment.